AGAP1 and cancer: Therefore, phenanthriplatin may act to modulate the cytoskeleton and cancer invasion through distinct pathways from those used by cisplatin, including a pathway incorporating AGAP1 and FilGAP signaling, while cisplatin signaling may not integrate this mechanism.